IP Library Granted Patent US 10,414,821
Granted Patent B2
US 10,414,821 · App. 15/328,462 · Granted Sep 17, 2019

Anti-PD-1 antibody and use thereof

Inventor: Jie Liu (Jinan, CN)
Assignee: LIVZON MABPHARM INC.
C07K16/2818A61K39/00115A61K39/39558C07K16/2809A61K39/0011A61K2039/505A61K2039/507A61P35/00C07K2317/24C07K2317/56C07K2317/565C07K2317/73C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,414,821
App. No.
15/328,462
Granted
Sep 17, 2019
Kind
B2
Abstract

A PD-1 antibody or a functional fragment thereof, and use of said antibody in the preparation of a medicament for treating tumors are provided.

Claims (8)

1. An antibody comprising a heavy chain and a light chain, which is capable of specifically binding to PD-1, wherein

the heavy chain comprises a heavy chain variable region which has the amino sequence represented by SEQ ID NO: 1, and the light chain comprises a light chain variable region which has the amino sequence represented by SEQ ID NO: 3; or

the heavy chain comprises a heavy chain variable region which has the amino sequence represented by SEQ ID NO: 4, and the light chain comprises a light chain variable region which has the amino sequence represented by SEQ ID NO: 6.

2. The antibody according to claim 1 , wherein

the heavy chain comprises a heavy chain variable region which has the amino sequence represented by SEQ ID NO: 4, and the light chain comprises a light chain variable region which has the amino sequence represented by SEQ ID NO: 6; and

wherein the antibody further comprises a human IgG4 or IgG1 heavy chain constant region and a human κ light chain constant region.

3. A pharmaceutical composition, which comprises the antibody according to claim 1 , and a pharmaceutically acceptable carrier.

4. A pharmaceutical composition, which comprises the antibody according to claim 2 , and a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2017
From: LIU, JIE
To: LIVZON MABPHARM INC.
Reel/Frame 042169/0934 →
Priority Claims (1)
CN 2014 1 0369300 · Jul 30, 2014 · national
Continuity (1)
Related Publication 20170210806A1 · Jul 27, 2017
Cited By (3)
US 12,312,405 US 12,503,512 US 12,624,397